EKF Diagnostics, the global diagnostics business, announces the successful assessment of its Quo-Test and Quo-Lab point-of-care HbA1c analyzers within the College of Medicine, Swansea University. Stephen Luzio, PhD, Associate Professor at the university, is giving a scientific poster presentation entitled “Assessment of two point-of-care analyzers for the determination of HbA1c.” at the World Diabetes Congress—International Diabetes Federation (IDF) 2013, this week in Melbourne, Australia.
Glycated hemoglobin (HbA1c) is widely used as a means of monitoring diabetes control and has recently been recommended for use as a method of diabetes diagnosis. Measurement of HbA1c with point-of-care analyzers (POCT) allows samples to be determined on site, while a patient is still in the clinic. Luzio and his team have successfully compared EKF’s Quo-Test and Quo-Lab POCT HbA1c analyzers with an established laboratory HPLC method, and have concluded that results are comparable to that of the HPLC method. “Both Quo-Test and Quo-Lab HbA1c POCT have the benefit of being able to generate results immediately in the clinical setting, providing greater convenience to the patient.”
Quo-Test and Quo-Lab use boronate fluorescence quenching technology to measure HbA1c from just 4 µL of capillary or venous blood and deliver results within four minutes. The Biosen C-Line analyzer, also being showcased in Melbourne, is used to measure glucose and lactate precisely and quickly, from 25 seconds, in clinics, laboratories, and sports medicine facilities. Read more and see video demonstrations of the Quo-Test and Quo-Lab point-of-care HbA1c analyzers.
